STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
Excluding rare disease therapies from a Medicare pilot program to lower drug prices would wipe out much of the savings from retail drugs, according to new research.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.
